Horizon secures FDA priority review for teprotumumab for treatment of active thyroid eye disease

This article was originally published here

The FDA grants Priority Review designation to applications for medicines that have the potential to provide significant improvements in the treatment of serious conditions. Priority Review is associated

The post Horizon secures FDA priority review for teprotumumab for treatment of active thyroid eye disease appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply